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T he fatty acid composition of plasma and erythrocyte 
phospholipids w as determined in children with various 
subtypes of epidermolysis bullosa (EB) and in their parents. 
~atients with recessive dys trophic, dominant dystrophic, 
sImplex, or junctional forms ofEB had a higher percentage 
composition of arachidonic acid in plasma and/or eryth-
rocyte phospholipids compared to age-matched controls. 
E pidermolysis bullosa patients treated with diphenylhy-
dantoin had lower levels o f arachidonic acid in plasma and 
erythrocyte phospholipids than did untreated EB patients. 
E pidermolysis bullosa (EB) is a g roup of inheritable diseases clinicall y characterized by a blistering re-sponse o f the skin to mild ph ys ical trauma [1] . The disease is classified into different fo rms determined by the specific histologic location of the skin lesion and 
th e mode of inheritance. In recessive dys trophic epidermolysis 
builosa (RD- EB) , the blistering occurs near the junction of the 
dermis and epidermis beneath the basal lamina. The m ain bio-
chemical abnormality so far associated w ith this fo rm of EB is 
increased synthesis of structurall y unstable collagenase [2,3J. Fi-
broblas ts cultured fro m RD- EB skin biopsies synthesize increased 
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Abbrevia tions: 
DD-EB: dominant dys trophic EB 
DPH: diphenylhydantoin 
EB: epidermolys is bullosa 
EB-S: EB simplex 
EFA: essential fa tty acid 
J-EB: junctional EB 
RD-EB: recessive dys trophic EB 
18:2n-6: linoleic acid 
20:3n-6: dihomo-gamma-linolenic acid 
20:4n-6: arachidonic acid 
22:4n-6: docosa tetraenoic acid 
22:5n-6: docosapentaenoic acid (n-6) 
18:3n-3: alpha-linolenic acid 
20:5n-3: eicosapentaenoic acid 
22:5n-3: docosapentaenoic acid (n-3) 
22:6n-3: docosahexaenoic acid 
Parents of children with the recessive dystrophic or junc-
tional EB s.ubtypes had higher linoleic and arachidonic acids 
in plasma and erythrocyte phospholipids than did controls . 
Plasma and erythrocyte total lipids were within the normal 
range in children with EB . Plasma zinc was also normal 
but plasma copper was eleva ted in children with recessive 
dys trophic EB. We conclude that higher arachidonic acid 
in plasma and erythrocytes m ay be related to the pathology 
of EB. J Invest D ermatol 89:395-399, 1987 
amounts of pros taglandins [4] and cyclic adenosine m onophos-
phate [5]. 
In addition to blistering of the skin, involvem ent of o ral mucous 
m embranes m ay predispose EB children to avoid foods that are 
not easily chewed and swall ow ed . As a result, th eir nutritional 
status may be compromised and this may partly account for grow th 
retardatio n and anemia. One such child with RD-EB was seen 
by two of us (S.c.c. and E. T.K. ) and his growth retardation , 
alopecia, and slowly healing scars were reminescent of the symp-
to ms of essential fa tty acid (EFA) defi ciency. Since RD-EB pa-
tients ha ve abnormal pros taglandin metabolism in skin fibroblas ts 
[4] and the inflammatory prostaglandins are derived fro m ara-
chidonic acid (20: 4n-6), it was considered possible that abnorm al 
EFA metabolism could contribute to increased synthesis and re-
lease of prostaglandins in RD-EB. 
We therefore considered it wo rth w hile to assess the nutritional 
status of patients w ith this disease. Specifi cally, in EB children 
and th eir parents, we have assessed the EFA content of plasm a 
and erythrocyte phospholipids that is generally a valid index of 
both E FA intake through the diet and abnormalities ofEFA me-
tabolism [6]. We have also quantitated' the m aj or lipid fractions 
in plasm a and erythrocytes in children with EB. Finally, zinc and 
copper in plas m a were analyzed because o f their important roles 
in EFA m etabolism [7] and beca use zinc trea tment has previously 
been attempted in a single case o f RD-EB [8]. 
MATERIALS AND M ETH O D S 
Patients We studied chil dren attendin g the EB clinic o f the 
Labora to ry fo r In ves tigative Derm atology at the Rockefell er Uni-
vers ity H ospital. Their age range was 1 to 15 years. Thirteen had 
RB-EB, one had do minant dys trophic EB (D D -E B), one had 
junctional EB O-EB), and one had EB sim plex (EB-S). Parents 
of children with RD-EB (1'1 = 6) and J-EB (/1 = 1) were also 
studied . Controls for the EB children were fro m Kentville, N ova 
Scotia, Canada and were age-matched. A sm all group of controls 
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for the EB parents were from N ew Yo rk (/'I = 8). This group 
was shown to have plasm a and erythrocyte fa tty acid profiles that 
were similar to th ose of adult controls fro m Kentville, N ova 
Scotia (/'I = 50). The fatty acid values of the control children from 
Kentville have no t been published before but those from the 
Kentville adults have been previously published [6]. Two 
RD-EB children w ere untreated at the time of sa mpling. Eleven 
RD-EB children received diphen ylhydantoin (DPH) in doses that 
maintained serum levels between 10 and 20 fLg/ml. 
Samples of blood were drawn from each patient and parent . 
Plasma and saline- washed erythrocy tes were frozen, coded, and 
shipped from N ew York to Kentville, N ova Scotia for lipid and 
fatty acid ana lys is. All blood samples were analyzed blind . 
Analytical Methods T he total lipid content of aliquots of plasma 
(1.0 ml) and erythrocytes (0.5 g) was extracted wi th chlorofo rm: 
methanol (2: 1) containing 0.02% butylated hydroxy toluene as 
antioxidant [6] . Aliqu ots of the tota l lipid extrac t o f both plasma 
and erythrocytes were analyzed for to tal choles terol by gas liquid 
chromatography using 5-alpha choles tan e as the internal standard 
[9] and for tota l phospholipids usin g the spectrophotom etric pro-
cedure and ammonium ferro thiocyanate reagent [1 0]. Plasm a total 
cholesterol and triacylglycerols were analyzed usin g an automated 
centrifugal analyzer and the appropriate reagent assay kit (instru-
m ent and assay kits from Cobas BI0, Roche D iagnostics, Nutley, 
N ew Jersey) . 
The total phospholi pid fraction of plas m a and erythrocytes was 
separa ted fro m the to tal lipid extract by thin-layer ch romatog-
raphy [9]. Fatty acids in this fraction were transmethylated using 
boron trifluoride-methanol. The fa tty acid m ethyl es ters were 
analyzed by gas-liquid chromatography using a H ewlett-Packard 
5880A gas chrom atograph with packed column, automated sam-
ple delivery, and peak integra tion (Hewlett-Packard Level IV) as 
previously described [9]. Fatty acid retention times were verified 
against those of authentic standards (NuC hek-Prep , Elysian, 
Minnesota). 
The pl asma content of zinc and copper was analyzed by flam e 
atomic absorption spectrophotom etry (In strumentation Labora-
to ries 457, Wilmington, M assachusetts) and appropriate precau-
tions were taken to minimize contamin ation . 
Statistics Two-way analysis of variance was used fo r compar-
isons of statistical differences between groups. Single speciman 
comparisons were assessed acco rding to Sokal and Rohlf (11]. 
RESULTS 
The composltlon o f EFA in plas ma phospholipids of child ren 
w ith vari ous forms of EB and of age m atched controls is shown 
in Table I. Initia lly, the fatty acid data was div ided into groups 
according to age (1-2y, 3-4y , 5- 10y, and 11-15y) but the EB data 
did not differ significantly with age, so, for the ease of presen-
tation, the da ta are not separated according to age. In RD-EB, 
linoleic acid (18:2n-6), arachidonic acid (20:4n-6), and docosa-
pentaenoic acid (22: 5n-6) were higher than in con trols, whereas 
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docosatetraenoic acid (22: 4n-6), docosapentaenoic acid (22: 5n-
3), and docosahexaenoic acid (22: 6n-3) were all lower than in 
controls. Samples were also obtained fro m single cases of DD-
EB, J-EB, and EB-S, none of w hich had detectable levels of alpha-
linolenic acid (18:3n-3) . The DD-EB and J-EB cases also had 
signifi can tly higher arachidonic acid than the control children 
(+ 70% and + 55%, respectively, p < 0.01), but in EB-S, ara-
chidonic acid was in the norm al range. Docosahexaenoic acid was 
significantly higher in the J-EB case than in the controls (+66% , 
p < 0.01) . 
In the erythrocyte phospholipids, RD-EB samples differed from 
controls in having higher linoleic acid , arachidonic acid , and do-
cosapentaenoic acid (n-6) as well as lower eicosapentaenoic acid 
(20: 5n-3) (Table II ). In J-EB and EB-S erythrocyte phospholipids, 
linoleic acid was no rmal but arachidonic acid was higher than in 
controls by 46% and 22%, respectively. As in the plasma phos-
pholipids, docosahexaenoic acid was 65% higher in the J-EB 
eryth rocyte phospholipids th an in the controls (Table II). 
M ost of the RD-EB children were being treated with DPH 
(/1 = 11) , but two children were untreated at the time blood 
samples were obtained. The effect of the DPH treatment on plasma 
and erythrocyte phospholipid fatty acid proflles was therefore 
compared between the two groups. From Table III it is apparent 
that the higher linoleic acid values in plasma and erythrocyte 
phospholipids in the overall g roup of children wi th RD-EB was 
due to the DPH treatment; the untreated children with RD-EB 
had similar linoleic acid values to the controls, whereas the eleven 
DPH-treated children with RD-EB had linoleic acid values 29% 
above the controls (p < 0.01). Untrea ted RD-EB children also 
had higher arachidonic acid than the controls (significant only in 
plas m a) . Arachidonic acid values in the plasma phospholipids o f 
the DPH-treated RD-EB cases were significantly lower than in 
the untreated cases. 
Fatty acids in plasm a and erythrocyte phos pholipids were ana-
lyzed in two sets of adult controls ; a large number from Kentville 
N ova Scotia (/1 = 50), data w hich have been previously published 
[6], and a small number from New York (/1 = 8, unpublished 
observations). Arachidonic acid w as lower in the plasma phos-
pholipids and linoleic acid was higher in the erythrocyte phos-
pholipids of the N ew Yo rk controls compared to the Kentville 
controls. Otherwise, the fatty acid co mposi tion was very similar 
in the two groups. Whether compared w ith the N ew York or 
Kentville controls, parents of the RD-EB children had higher 
linoleic acid and arachidonic acid but lower docosatetraenoic acid 
in plasma and erythocyte phospholipids and lower docosapen-
taenoic acid (n-6) in erythrocyte phospholipids (Table IV). The 
single parent from a child with J-EB had similar fatty acid ab-
normalities as the parents o f the RD-EB children . 
Plasma and erythrocyte lipids were also quantitated in the EB 
children and controls (Table V) . Some individual EB cases had 
plasm a lipid values m arkedl y lower than in con trols, e. g., triacyl-
glycerol in the DD-EB, J-EB , and EB-S cases, and low total 
phospholipids in two of the RD- EB cases, w hich were 50 to 60% 
Table I. EFA Composition (%) of P lasma Phospholipids From C hildren With EB 
Controls RO-EB OO-EB J-EB EB-S 
(/I = 104) (1/ = 13) (1/ = 1) (1/ = 1) (1/ = 1) 
18:211-6 21.9 ± 3.7 27.2 ± 4.0" 21.9 22.0 25.1 
20:311-6 3.4 ± 0.6 3.2 ± 0.7 5.0b 2.1 5.0b 
20:4n-6 10.7 ± 2.2 12.2 ± 1.6" 18.2b 16.6" 12.5 
22:4n-6 0.8 ± 0.3 0.4 ± 0.1" 0.5 0.4 0.4 
22:511-6 0.4 ± 0.2 1.0 ± 0.2" 1.2" 0.7 1. 0" 
18:3n-3 0.4 ± 0.2 0.4 ± 0.2 NO/' N Ob NO" 
20:511-3 0.6 ± 0.3 0.5 ± 0.2 0.6 0.5 0.7 
22:5n-3 1.0 ± 0.2 0.6 ± 0.2" 0.8 0.7 1.0 
22:611-3 3.5 ± 1.1 2.7 ± 0.7" 2.7 5.8" 2.2 
Values are the mean :!: SO. Eleven of the RD-EB cases were receiving DPH when the blood samples were drawn. NO, not detected «0.01 % of to tal fatt y acids). 
up < 0.01 compared to contro ls (ANOVA and Duncan 's mu ltiple range test). 
'p < 0.01 co mpared to controls (ANOVA - single specimen comparison). 
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Table II. EFA Composition (%) of Erythrocyte Phospholipids From C hildren With EB 
Controls RO-EB 
(/I = 104) (/I = 13) 
J-EB 
(/I = I) 
EB-S 
(n = 1) 
18:2n-6 11.2 ± 2.3 13.5 ± 2.6" 11 .9 10.4 
2.5 
19.9d 
3.6 
2. 1' 
N O' 
2.3 
2.6 
20:3n-6 1.9 ± 0.5 1. 9 ± 0.5 1.3 
20:411-6 16.3 ± 2.5 19.4 ± 1.41> 23.8' 
22:4n-6 3.6 ± 1.1 3.5 ± 0.7 2.7 
22:511-6 0.7 ± 0.2 1. 6 ± 0.61> 1.0 
20:511-3 0.6 ± 0.2 0. 4 ± 0.2" 0.6 
22:5n-3 2.1 ± 0.5 1.9 ± 0.5 2.1 
22:6n-3 4.6 ± 1.5 3.5 ± 0.7 7.6'/ 
Values arc the mean :;: SO. Eleven of the RD-EB cases were treated wi th diphenylhydantoin at the time of sa mpling. NO, not detected «0.01 % of tota l fatt y acids). 
'p < 0.05 and 'p < 0.01 com pared to con trols (A N OY A and Duncan 's multiple range test) . 
'p < 0.01 and Jp < 0.05 co mpared to controls (ANOY A, single specimen comparison). 
Table III. Composition (%) of n-6 EFA in Pl as ma and 
Erythrocyte Phos pholipids in Controls and in Children 
With RB-EB 
RO-EB 
Controls OPH(-) OPH(+) 
(1/ = 104) (/I = 2) (/1 = 11 ) 
Plasma 
18:2n-6 21. 9 ± 3.7 24.5, 18.7 28.2 ± 3.2,,·b 
20:3n-6 3.4 ± 0.6 2.5,2.6 3.3 ± 0.7 
20:4n-6 10.7 ± 2.2 13.7, 15.51> 11 .8 ± 1. 3,,·b 
Erythrocytes 
18:2n-6 11.2 ± 2.3 10.7,9.7 14.2 ± 2.3,·b 
20:3n-6 1. 9 ± 0.5 1.4, 1.4 2.0 ± 0.5 
20:4n-6 15.3 ± 4.5 20.1 , 21.1 19.2 ± 1.4" 
22:411-6 3.6 ± 1.1 3.9, 4.3 3. 4 ± 0.7 
22:5n-6 0.7 ± 0.2 1.4, 2.2 1. 6 ± 0.6" 
The RD-EB cases have been sepa rated postanalysis according to whether they 
w ere receiving DPH . Values arc the mean ± SO. 
' p < 0.0 1 com pared to co ntrols (A NOYA and Dunca n's mu ltiple range test). 
.p < 0.0 1 compared to DPH( -) (A N OYA, single specimen compa rison). 
o~ control values. However, as a group they did not have sig-
~fican tl y lower plasma lipids than did the controls. Erythrocyte 
lipIds (phospholipid and cholesterol) in the RD-EB children also 
did not differ significantl y from control values (Table V). N ever-
theless, in the J- EB case, erythrocyte cholesterol was 34% higher 
than control (p < 0.01) and in the EB-S case, erythrocyte phos-
pholipids were 29% above control (p < 0.01). 
In the RD-EB children, plas ma zinc was w ithin the normal 
range (90 ± 12 ,ug/dl) , but plas ma copper was signifi cantl y higher 
than normal (160 ± 39 vs. 96 ± 12 ,ug/dl , p < 0.01). 
DISCUSSION 
T he fatty acid analyses show a higher percentage composition of 
linoleic acid andlor arachidonic acid in plas ma and erythrocyte 
phospholipids in children w ith various fo rms of EB compared to 
age- matched controls. Since EFA-deficien t indi viduals have low 
linoleic and arachidonic acids, our resu lts suggest that the genera l 
EFA status of children with EB is adequate and do no t support 
our o riginal hypothesis that children w ith EB could be EFA-
defi cient. However, there was a characteristic alteration in the 
plasma and erythrocyte EFA profi les in EB that va ried only slightly 
between EB subtypes; except in the pl as ma of the EB-S subtype, 
arachidonic acid was eleva ted in the plas ma and erythrocyte phos-
pholipids of all the EB subtypes. Compared w ith other skin dis-
eases in which plas ma o r erythrocyte EFA patterns have been 
described (1 2-1 4) and in which arachidonic acid is generaLl y de-
creased , the EFA changes in EB are distin ctive in having increased 
arachidonic acid. 
By providing additional substrate, the higher content of ara-
chidonic acid in plasma and erythrocyte phospholipids may be 
related to increased prostaglan din production by RD-EB skin 
fibroblasts (4]. Since arachidonic acid is no t sy nthesized by the 
skin (15], its presence in the skin is a result of its transport from 
the blood. Despite the arachidonic acid being 14% increased in 
plasma phospholipids, quantitati vely, phospholipids were re-
duced by 28% in EB plas ma. T hus, the quantitative amount of 
arachidonic acid carried by the plasma phospholipids (,ug/g) was 
actuall y lower in EB children than in the cont rols. N evertheless, 
Table IV. EFA (%) in Plas ma and Erythrocyte Phospholipids of Kent ville (Reference 6) and N ew York Adu lt Controls as 
Compared to Parents of C hildren With EB 
Controls EB Pa rents 
Kel1 tville New York RO-EB 
(n = 50) (1/ = 8) (1/ = 6) 
Plasma 
18:2n-6 22.8 ± 2.7 21. 8 ± 0.9 27.2 ± 1. 9" 
20:311-6 3.1 ± 0.6 2.9 ± 0.3 2.8 ± 0.6 
20:4n-6 11.4 ± 1.7 8.5 ± 0.6" 13.1 ± 2.0/' 
22:411-6 0.7 ± 0.3 1.0 ± 0. 1 0.3 :;: 0.1 " 
Erythrocytes 
18:211-6 9.8 ± 1.6 12.8 ± 0.6" 15. 1 ± 1.1 " 
20:3n-6 1.4 ± 0. 1 1.3 ± 0. 1 1. 6 :;: 0.3 
20:4n-6 15.1 ± 2.0 15.2 ± 0.3 18.6 ± 3.0" 
22:4n-6 5.5 ± 1.4 4.2 ± 0.4 3.1 ± 0.9" 
22:5n-6 4.0 ± 1. 9 3.6 ± 0.6 1.0 ± 0.4" 
V alues arc the mea n :;: SO. ' P < 0.0 1, and bp < 0.05 compared to Kentville controls (ANOYA and Dun can's mu lti ple range test). 
'p < 0.05, and 'p < 0.0 1 compared to Kcntville controls (ANOY A, single specimen compa risons). 
J-EB 
(1/ = 1) 
27.8' 
1. 8' 
15.5'/ 
0.2' 
12.8' 
1.1 ,/ 
19. 1' 
2.9d 
0.7' 
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Table V. Plasma and Erythrocyte Lipids in Children With EB Compared to Age-Matched Controls 
Controls RD-EB DD-EB j-EB EB-S 
(II = 14) (n = 13) (n = 1) (n = 1) (II = 1) 
Plasma (mg/dl) 
Triacylglycerol 128 ± 58 104 ± 46 54" 55" 138 
C holesterol 173 ± 44 144 ± 28 157 144 186 
Phospholipids 174 ± 50 135 ± 28 155 149 183 
Erythrocytes (mg/g) 
C holesterol 0.83 ± 0.12 0.94 ± 0.08 0.74 1.11" 0.85 
Phospholipids 1. 91 ± 0.34 2.37 ± 0.45 NA 2.14 2.46" 
C holesterol/phospholipid 0.44 ± 0.06 0.40 ± 0.05 NA 0.52b 0.35" 
Values arc the mean :!: SO. NA , erythrocyte sample not available. 
")1 < 0.05 and ")1 < 0.01 compared to controls (ANOV A, single specimen comparisons). 
arachidonic acid in erythrocytes of EB children was more than 
double that in normal children (204 vs 484 J,Lg/g) . H ence, eryth-
rocytes may potentially be responsible for providing additional 
arachidonic acid to the skin and thereby permitting the increased 
prostaglandin synthesis previously described in skin fibrobl as ts 
from RD-EB cases [4] . Abnormal arachidonic acid transport may 
therefore be important in the pathogenesis of the dermal lesions 
in EB . It remains a distinct possibility that leukotrienes (pro-
edema and pro-inflammatory metabolites of arachidonic acid syn-
thesized via the lipoxygenase pathway) are also synthesized in 
excess in EB skin, especially at the time that the skin lesions are 
present. 
Diphenylhydantoin has been used with some success in treatin g 
RD-EB [1 6,1 7]. Its beneficial effects in EB are thou ght to involve 
inhibition of excess collagenase activity [17]. Our results suggest 
that the benefi cial effects ofDPH may occur in part by decreasing 
blood levels of arachidonic acid (Table Ill) . After an average pe-
riod of treatment with DPH of2 to 6 months, phospholipid levels 
of arachidonic acid were significantly lower in all plasma samples 
and nonsignificantly lower in 9 of 11 erythrocyte samples com-
pared to untreated RD-EB cases. Diphenylhydantoin-treated RD-
EB children also had increased levels of the fatty acids that are 
arachidonic acid precursors (linoleic and dihomo-gamma- lino-
lenic acids), suggesting the mechanism of DPH's effect on ara-
chidonic acid levels may occur through inhibition of arachidonic 
acid synthesis. Diphenylhydantoin has also been shown to be a 
competitive antagonist of prostaglandin effects in vascular tissue 
[18] . Therefore, in addition to its effects on collagenase, DPH 
may be effective in EB by reducing the synthesis of the main 
prostaglandin precursor (arachidonic acid) and by competitively 
antagonizing prostaglandin effects in the skin. 
Fatty acids were also analyzed in the plasma and erythrocyte 
phospholipids of parents of some of the children w ith RD-EB 
and one parent of a child w ith J-EB (Table IV) . Like the EB 
children, the parents also had higher linoleic acid and arachidonic 
acid in plasma and erythrocyte phospholipids as well as lower 
docosatetraenoic acid in plasma. Unlike the RD-EB children, who 
had a 2.3X hi gher docosapentaenoic acid (n-6) in erythrocyte 
phospholipids, the parents had very significantly lower docosa-
pentaenoic acid (n-6) in erythrocyte phospholipids (20 to 25% of 
controls, p < 0.01). Unaffected parents would therefore appear 
to be carriers of some but not all of the EFA abnormalities present 
in children with EB and, as well, have distinct EFA abnormalities 
in erythrocyte phospholipids not carried by their affected children. 
Other analyses performed were of a general lipid and nutritional 
nature. Plasma and erythrocyte levels of phospholipids, triacyl-
glycerols, and cholesterol were within normal limits in the chil-
dren with EB and in their parents. N evertheless, in individual 
cases of DD-EB and J-EB, bo th triacylglycerols and phospho-
lipids in plasma were 50 to 60% lower than in controls, suggesting 
possible nutritional inadequacies in these cases. 
Plasma zinc was within normal limits in the EB cases of all 
subtypes, confirming si milar observations made previously [8]. 
Hence, our preliminary analytical evidence suggests that overt 
zinc deficiency does not exist in EB, a conclusion that supports 
the previous observation that zinc supplementation in RD-EB is 
ineffective [8]. Plasma co pper was significantly higher in the 
RD-EB children than in their parents or in the controls. In view 
of the predictable rise in plasma copper in conditions of infection 
or inflammation [1 9], higher plasma copper would not necessarily 
be relevant to EB per se, in which epidermal infection is a chronic 
problem. As with the EFA profiles, our data suggests that dietary 
zinc and copper status in EB children is probably adequate. Hence, 
the malnutrition and iron-deficiency anemia that is apparent in 
many EB children is apparentl y not associated w ith dietary or 
metabolically induced EFA deficiency . 
Future treatments for EB may be able to incorporate our fa tty 
acid findings. The overabundance of arachidonic acid appears to 
be a potential factor contributing to the pathology of EB. Less 
obvious, but perhaps as important is the lower overall values for 
the n-3 fatty acids in both plasma and erythrocytes of the 
RD-EB cases, the total absence of alpha-linolenic acid (18:3n-3) 
in the plasma phospholipids of the DD-EB, J-EB , and EB-S cases 
and the absence of eicosa pentaenoic acid (20:5n-3) in the eryth-
rocyte phospholipids of the EB-S case. Since n-3 fatty acids , e.g., 
eicosapentaenoic acid and docosahexaenoic acid in oils extacted 
from marine fi sh, compete with arachidonic acid for incorpora-
tion into membrane phospholipids and are perhaps the most ef-
fective natural blockers of arachidonic acid metabolism to the 
prostaglandins and leukotrienes [20,21] (both of which cause acute 
inflammation and edema indistinguishable from the blisters seen 
in RD-EB), they may have a beneficial role in the future treatment 
ofEB. . 
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